Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941330 · ClinicalTrials.gov registry record · Phase 2
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00941330 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 31 participants.
The verdict
NCT00941330, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The patients are being asked to take part in this study because they have a hormone receptor-positive breast cancer (contains estrogen and/or progesterone receptors) and their doctor has told them that they have an option to receive chemotherapy or hormonal therapy before surgery. The purpose of this study is to assess if chemotherapy using docetaxel and cytoxan (TC) or hormonal therapy using exemestane can shrink the size of their breast tumor and allow them to preserve the breast or have less extensive surgery on their breast.
Interventions
- DRUG Docetaxel
- DRUG Exemestane
- DRUG Cytoxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00941330
The ClinicalTrials.gov registry entry for NCT00941330 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00941330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00941330 about?
NCT00941330 is a clinical study titled "Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers". The patients are being asked to take part in this study because they have a hormone receptor-positive breast cancer (contains estrogen and/or progesterone receptors) and their doctor has told them that they have an option to receive chemotherapy or hormonal therapy before surgery. The purpose of thi...
What is the current status of trial NCT00941330?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2009-07. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00941330?
The interventions under investigation include: Docetaxel (DRUG), Exemestane (DRUG), Cytoxan (DRUG).
Who is sponsoring clinical trial NCT00941330?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.